Molecular Targeting of Developmental Cancers in Children

儿童发育性癌症的分子靶向

基本信息

项目摘要

DESCRIPTION (provided by applicant): This Program Project proposes an interactive multidisciplinary program of research into the genetics, molecular pharmacology, immunology and experimental therapy of the malignancies of the developing nerve, bone and muscle affecting children. The overall objective is: the identification, functional analysis and targeted therapeutic modification of genes and gene products uniquely or differentially expressed by the developmental malignancies of childhood. The Program Project has 4 research projects and 5 cores. Project I proposes to identify distinctive signatures of gene expression that define therapeutically relevant subclasses of these developmental tumors and to identify genes and pathways that provide potential targets for drug and immune-based therapy by virtue of their differential expression or altered function. Project II proposes to evaluate the function of the unique fusion genes that characterize Ewing's sarcoma, alveolar rhabdomyosarcoma and desmoplaslic small round cell tumor (DSRCT), to identify their targets and to characterize the alterations in gene expression and tumor cell function associated with their inhibition. Project IV proposes to evaluate novel ScFv streptavidin conjugate-based strategies for delivering radioconjugates, cytokines or effector cells to tumors to enhance tumor targeted activity and to reduce toxicities currently associated with non-specific uptake of native antibodies or antibody conjugates in organs such as the liver or the kidneys. Project V proposes to evaluate the anti-tumor activity of T lymphocytes generated from the blood of tumor bearing and normal hosts by sensitization with peptides derived from oncofetal proteins differentially expressed by developmental tumors of childhood. Practicable strategies will also be developed for generating T cells specific for peptides derived from these oncofetal proteins from patients not sharing common HLA alleles. The anti-tumor activity of T cells specific for novel epitopes will be compared with that of T cells generated against known immunogenic tumor peptides, as will be their capacity to home to and induce regressions of tumors in xenografted mice. Based on these studies, a phase I trial evaluating T cells specific for WT1 peptides in the treatment of WT1 malignancies of childhood will be conducted. The Program Project also includes 5 cores, a Pathology Core for evaluation of clinically annotated specimens, a Clinical Core to ensure appropriate accrual and careful evaluation of uniformly treated patients afflicted with these developmental tumors, a Preclinical Testing Core to assess and validate the activity of agents targeting genes or gene pathways found to be differentially expressed in specific developmental tumors against well-characterized tumor cell lines and, as appropriate, patient derived tumor cell populations both in vitro and in NOD/SClD xenograft models, a Biostatistics Core to guide the design of experiments in in vitro and in vivo models and to provide relational bioinformatic support for analyses of patterns of gene expression and an Administrative Core to enhance communication, prioritize efforts and provide appropriate scientific interchange and oversight.
描述(由申请者提供):这个项目提出了一个互动的多学科研究计划,研究影响儿童的发育中的神经、骨骼和肌肉的恶性肿瘤的遗传学、分子药理学、免疫学和实验治疗。总体目标是:对儿童发育性恶性肿瘤独特或不同表达的基因和基因产物进行鉴定、功能分析和有针对性的治疗修饰。该计划项目有4个研究项目和5个核心。项目I建议识别定义这些发育性肿瘤的治疗相关亚类的独特基因表达特征,并识别因其差异表达或功能改变而为基于药物和免疫的治疗提供潜在靶点的基因和途径。项目二建议评估尤文氏肉瘤、肺泡型横纹肌肉瘤和结缔组织增生性小圆细胞肿瘤(DSRCT)特有的融合基因的功能,以确定它们的靶点,并表征与它们的抑制相关的基因表达和肿瘤细胞功能的变化。项目四建议评估基于单链抗体亲和素结合物的新策略,将放射性结合物、细胞因子或效应细胞输送到肿瘤,以增强肿瘤靶向活性,并减少目前与在肝脏或肾脏等器官中非特异性摄取天然抗体或抗体结合物相关的毒性。项目V建议通过用儿童发育性肿瘤差异表达的癌胎儿蛋白的多肽致敏,评估从荷瘤患者和正常宿主的血液中产生的T淋巴细胞的抗肿瘤活性。还将开发切实可行的策略,以产生针对来自不具有共同等位基因的患者的癌胎儿蛋白的多肽的特异性T细胞。针对新表位的T细胞的抗肿瘤活性将与针对已知免疫原性肿瘤多肽产生的T细胞的抗肿瘤活性进行比较,以及它们在异种移植小鼠中归宿和诱导肿瘤退化的能力。在这些研究的基础上,将进行一项评估WT1多肽特异性T细胞治疗儿童WT1恶性肿瘤的I期试验。该计划项目还包括5个核心,一个用于评估临床注释样本的病理学核心,一个用于确保对患有这些发育性肿瘤的接受统一治疗的患者进行适当收益和仔细评估的临床核心,一个临床前测试核心,用于评估和验证针对在特定发育性肿瘤中发现差异表达的基因或基因通路的药物的活性,该药物在体外和在NOD/SCLD异种移植模型中适当地针对患者来源的肿瘤细胞群,一个生物统计学核心,用于指导体外和体内模型的实验设计,并为基因表达模式的分析提供相关的生物信息学支持,以及一个行政核心,以加强沟通,确定努力的优先顺序,并提供适当的科学交流和监督。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard John O'REILLY其他文献

Richard John O'REILLY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard John O'REILLY', 18)}}的其他基金

EBV Specific T-cells from 3rd party donors for treatment of EBV-associated malign
来自第三方捐赠者的 EBV 特异性 T 细胞,用于治疗 EBV 相关恶性肿瘤
  • 批准号:
    8189121
  • 财政年份:
    2011
  • 资助金额:
    $ 251.11万
  • 项目类别:
EBV Specific T-cells from 3rd party donors for treatment of EBV-associated malign
来自第三方捐赠者的 EBV 特异性 T 细胞,用于治疗 EBV 相关恶性肿瘤
  • 批准号:
    8334495
  • 财政年份:
    2011
  • 资助金额:
    $ 251.11万
  • 项目类别:
A Retrospective and Cross- Sectional Study of Hematopoietic Cell Transplantation
造血细胞移植的回顾性横断面研究
  • 批准号:
    8326283
  • 财政年份:
    2009
  • 资助金额:
    $ 251.11万
  • 项目类别:
DEVELOPMENT & EVALUATION OF PRACTICABLE APPROACHES FOR GENERATION OF CYTOTOXIC &
发展
  • 批准号:
    7318391
  • 财政年份:
    2007
  • 资助金额:
    $ 251.11万
  • 项目类别:
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE
同种异体干细胞移植治疗淋巴造血障碍的临床试验
  • 批准号:
    7318393
  • 财政年份:
    2007
  • 资助金额:
    $ 251.11万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    7318398
  • 财政年份:
    2007
  • 资助金额:
    $ 251.11万
  • 项目类别:
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth
阿蒂夫。
  • 批准号:
    7136183
  • 财政年份:
    2006
  • 资助金额:
    $ 251.11万
  • 项目类别:
Molecular Targeting of Developmental Cancers in Children
儿童发育性癌症的分子靶向
  • 批准号:
    7096001
  • 财政年份:
    2005
  • 资助金额:
    $ 251.11万
  • 项目类别:
Core D
  • 批准号:
    7129460
  • 财政年份:
    2005
  • 资助金额:
    $ 251.11万
  • 项目类别:
Cellular Immunity Targeting Epithelial Ovarian Cancer
针对上皮性卵巢癌的细胞免疫
  • 批准号:
    6952122
  • 财政年份:
    2005
  • 资助金额:
    $ 251.11万
  • 项目类别:

相似国自然基金

Pre-targeting/Click反应介导的自体循环干细胞在心脏缺血损伤修复中的应用及机制研究
  • 批准号:
    81873493
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Inhibiting RNA polymerase I by targeting the RPAC1/RPAC2 protein interaction highlighted by developmental disorders
通过针对发育障碍突出显示的 RPAC1/RPAC2 蛋白相互作用来抑制 RNA 聚合酶 I
  • 批准号:
    EP/Y000897/1
  • 财政年份:
    2024
  • 资助金额:
    $ 251.11万
  • 项目类别:
    Research Grant
Targeting developmental cell states in melanoma
针对黑色素瘤的发育细胞状态
  • 批准号:
    MC_UU_00035/13
  • 财政年份:
    2023
  • 资助金额:
    $ 251.11万
  • 项目类别:
    Intramural
Developmental neuroendocrine toxicity targeting the kisspeptin pathway
针对 Kisspeptin 通路的发育神经内分泌毒性
  • 批准号:
    10608824
  • 财政年份:
    2022
  • 资助金额:
    $ 251.11万
  • 项目类别:
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment
选择性靶向癌细胞和肿瘤基质室中 MEK-ERK 通路的发育疗法
  • 批准号:
    10092258
  • 财政年份:
    2021
  • 资助金额:
    $ 251.11万
  • 项目类别:
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment
选择性靶向癌细胞和肿瘤基质室中 MEK-ERK 通路的发育疗法
  • 批准号:
    10589930
  • 财政年份:
    2021
  • 资助金额:
    $ 251.11万
  • 项目类别:
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment
选择性靶向癌细胞和肿瘤基质室中 MEK-ERK 通路的发育疗法
  • 批准号:
    10386764
  • 财政年份:
    2021
  • 资助金额:
    $ 251.11万
  • 项目类别:
Developmental drug study targeting PARK7/DJ-1, a causetive gene of familial Parkinson's disease
针对家族性帕金森病致病基因 PARK7/DJ-1 的开发药物研究
  • 批准号:
    18K06904
  • 财政年份:
    2018
  • 资助金额:
    $ 251.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Developmental Evaluation Targeting Japanese Language Education Program at University Level: What is the Sustainable and Useful Developmental Evaluation?
针对大学日语教育项目的发展评估:什么是可持续且有用的发展评估?
  • 批准号:
    17K02863
  • 财政年份:
    2017
  • 资助金额:
    $ 251.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Developmental studies to inform clinical stratification and targeting of SHH MB
为 SHH MB 的临床分层和靶向提供信息的发展研究
  • 批准号:
    9884737
  • 财政年份:
    2016
  • 资助金额:
    $ 251.11万
  • 项目类别:
Developmental studies to inform clinical stratification and targeting of SHH MB
为 SHH MB 的临床分层和靶向提供信息的发展研究
  • 批准号:
    9037110
  • 财政年份:
    2016
  • 资助金额:
    $ 251.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了